



## State CHEST Conference

**YaleCME**  
CONTINUING MEDICAL EDUCATION

Presented by

Yale School of Medicine's Department of Internal Medicine - Section of Pulmonary, Critical Care & Sleep Medicine

# Hypersensitivity Pneumonitis



## Mridu Gulati, MD

Associate Professor of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine  
Yale School of Medicine

Associate Director, Yale Interstitial Lung Disease Program  
Yale Center Director, Pulmonary Fibrosis Care Center Network  
Director, Sarcoidosis Clinic, Yale School of Medicine

**Wednesday, January 22, 2020 @ 3-4 pm**  
Fitkin Amphitheatre

**Moderator: Danielle Antin-Ozerkis, MD**

*There is no corporate support for this activity*

This course will fulfill the licensure requirement set forth by the State of Connecticut

### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### TARGET AUDIENCE

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

### NEEDS ASSESSMENT

Hypersensitivity pneumonitis (HP) is a form of interstitial lung disease incited by exposure to mostly organic antigens occurring in susceptible individuals. Fibrotic and non-fibrotic HP forms exist. The contribution of exposures to interstitial lung diseases is often overlooked; however, identification and subsequent exposure cessation can lead to clinical improvement and even in patients with fibrotic disease or/stabilization of disease in the appropriate settings. In addition to clinical history, several radiographic and pathologic clues should signal a search for a possible antigen. Corticosteroids and immunosuppression may have a role. Additionally, there is a growing interest in a possible role for anti-fibrotics for fibrotic HP patients.

### LEARNING OBJECTIVES

At the conclusion of this activity, participants will:

1. To understand the diagnostic approach to fibrotic and non-fibrotic interstitial lung disease
2. To understand the basic treatment approach
3. To develop a basic understanding of the principles of exposure assessment including both its importance and limitations

### DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### FACULTY DISCLOSURES

Richard Matthay, MD, Course Director – No conflict of interest  
Mridu Gulati, MD – France Foundation, Boehringer Ingelheim  
It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.